// Applications
The Phoenix Platform™ supports applications across human and animal health, encompassing laboratory studies, preclinical research, human clinical experience, and commercial development through Phoenix Animal Wellness.
// human health
Peer-reviewed laboratory and animal studies report antiviral activity of defined PBI extracts against enveloped viruses, including published in vitro data and findings from an animal model of SARS-CoV-2 infection. PBI-06150 is the lead candidate in this area and is being developed for acute respiratory viral infection using a host-directed strategy.
Published preclinical research reports selective activity against malignant human cells that overexpress the alpha-3 isoform of Na,K-ATPase, along with glioblastoma findings involving GRP78-related stress biology. PBI-05204 was evaluated in Phase I and Phase II human studies involving advanced solid tumors and pancreatic cancer.
PBI-sponsored preclinical research conducted at Duke University reported increased brain-derived neurotrophic factor (BDNF) and protection of neural tissue following oxygen-glucose deprivation. These findings support continued investigation in models relevant to ischemic stroke and neurodegenerative disease. Separately, PBI is evaluating an emerging triterpene-based composition within its neuroprotection program.
// animal health
Phoenix Animal Wellness (PAW) is a separate animal-health company commercializing applications informed by the Phoenix Platform™. Phoenix Biotechnology develops the scientific platform and is a significant shareholder in PAW. This relationship extends the platform into animal health while maintaining distinct organizations, operations, and development priorities.
PBI and PAWEvidence Standards
Phoenix Biotechnology distinguishes among laboratory findings, preclinical evidence, human clinical experience, investigational development, and commercial animal-health activity. Each application is described according to the maturity and context of its supporting evidence.
